Altace Revascularization Benefit Is Clear But Inappropriate For Label - Cmte.
Executive Summary
King Pharmaceuticals' ACE inhibitor Altace is clearly beneficial in reducing the need for revascularization, but inclusion of the claim in labeling may inappropriately influence clinical practice, members of FDA's Cardio-Renal Drugs Advisory Committee said.
You may also be interested in...
King Altace Label Highlights Data Supporting Efficacy In Diabetic Patients
Labeling for King Pharmaceutical's ACE inhibitor Altace has been updated to highlight substudy data supporting efficacy in diabetic patients, following FDA approval Oct. 5 for reduction in risk of myocardial infarction, stroke and death from cardiovascular causes.
King Altace Label Highlights Data Supporting Efficacy In Diabetic Patients
Labeling for King Pharmaceutical's ACE inhibitor Altace has been updated to highlight substudy data supporting efficacy in diabetic patients, following FDA approval Oct. 5 for reduction in risk of myocardial infarction, stroke and death from cardiovascular causes.
Altace Will Gain 1,000 Wyeth Reps Through Copromotion Deal
Wyeth-Ayerst is allocating approximately 1,000 sales reps to promote King's Altace in the U.S. and Puerto Rico, under a copromotion agreement announced June 23.